CD274 and breast carcinoma: In breast cancer mouse models, treatment with sulfamethoxazole, macitentan, and anti–PD-L1 antibodies significantly decreased plasma exo-PD-L1 levels, reactivated cytotoxic T cells, and led to reduced tumor growth and metastasis (94–96).